Literature DB >> 23907290

SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013.

A Redondo1, J Cruz, A Lopez-Pousa, F Barón.   

Abstract

The diagnosis and treatment of osteosarcoma should be performed by an experienced multidisciplinary team. Considering it is a systemic disease, chemotherapy is essential for long-term success. The drugs most commonly used are: cisplatin, adriamycin, high-dose methotrexate, ifosfamide, etoposide, and, more recently, mifamurtide. The neoadjuvant chemotherapy allows to know tumour chemosensitivity and getting the main prognostic factor: the percentage of tumour necrosis. In addition to chemotherapy, it is important to conduct surgical resection of primary tumour with wide margins, and in disseminated disease also to attempt resection of pulmonary metastasis.

Entities:  

Mesh:

Year:  2013        PMID: 23907290     DOI: 10.1007/s12094-013-1087-0

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  19 in total

1.  Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology.

Authors:  J C Gentet; M Brunat-Mentigny; M C Demaille; F Pein; H Avet-Loiseau; C Berger; L De Lumley; H Pacquement; C Schmitt; E Sariban; P Pillon; J L Bernard; C Kalifa
Journal:  Eur J Cancer       Date:  1997-02       Impact factor: 9.162

2.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

Authors:  M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick
Journal:  N Engl J Med       Date:  1986-06-19       Impact factor: 91.245

4.  Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study Group.

Authors:  S S Bielack; B Kempf-Bielack; U Heise; D Schwenzer; K Winkler
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

Review 5.  Osteosarcoma: a multidisciplinary approach to diagnosis and treatment.

Authors:  James C Wittig; Jacob Bickels; Dennis Priebat; James Jelinek; Kristen Kellar-Graney; Barr Shmookler; Martin M Malawer
Journal:  Am Fam Physician       Date:  2002-03-15       Impact factor: 3.292

6.  A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.

Authors:  G Grignani; E Palmerini; P Dileo; S D Asaftei; L D'Ambrosio; Y Pignochino; M Mercuri; P Picci; F Fagioli; P G Casali; S Ferrari; M Aglietta
Journal:  Ann Oncol       Date:  2011-04-28       Impact factor: 32.976

7.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Authors:  Paul A Meyers; Cindy L Schwartz; Mark D Krailo; John H Healey; Mark L Bernstein; Donna Betcher; William S Ferguson; Mark C Gebhardt; Allen M Goorin; Michael Harris; Eugenie Kleinerman; Michael P Link; Helen Nadel; Michael Nieder; Gene P Siegal; Michael A Weiner; Robert J Wells; Richard B Womer; Holcombe E Grier
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

8.  High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions.

Authors:  Gaetano Bacci; Michele Rocca; Mariacristina Salone; Alba Balladelli; Stefano Ferrari; Emanuela Palmerini; Cristiana Forni; Antonio Briccoli
Journal:  J Surg Oncol       Date:  2008-11-01       Impact factor: 3.454

9.  Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.

Authors:  G Bacci; P Picci; S Ferrari; P Ruggieri; R Casadei; A Tienghi; A Brach del Prever; F Gherlinzoni; M Mercuri; C Monti
Journal:  Cancer       Date:  1993-12-01       Impact factor: 6.860

10.  Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

View more
  3 in total

1.  SEOM guidelines 2013: a response to the needs of Spanish oncologists.

Authors:  J J Cruz-Hernández; C A Rodríguez
Journal:  Clin Transl Oncol       Date:  2013-08-08       Impact factor: 3.405

Review 2.  Osteosarcoma Overview.

Authors:  Brock A Lindsey; Justin E Markel; Eugenie S Kleinerman
Journal:  Rheumatol Ther       Date:  2016-12-08

3.  Identification of pyroptosis-related genes and long non-coding RNAs signatures in osteosarcoma.

Authors:  Jian Zhang; Jianjian Deng; Rui Ding; Jinghong Yuan; Jiahao Liu; Xiaokun Zhao; Tianlong Wu; Jingyu Jia; Xigao Cheng
Journal:  Cancer Cell Int       Date:  2022-10-16       Impact factor: 6.429

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.